Skip to main content

Avalo Therapeutics, Inc.

corporate_fare Company Profile

Avalo Therapeutics, Inc.

AVTX·NASDAQ·Life Sciences·CIK 0001534120

The company is a clinical stage biotechnology company focused on developing treatments for immune-mediated inflammatory diseases using IL-1β-based therapies. Its primary product candidate is abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody. Abdakibart (AVTX-009) is currently in a Phase 2 clinical trial for hidradenitis suppurativa (HS), known as the LOTUS trial. The company aims to complete this Phase 2 trial and prepare for anticipated topline data readout in the second quarter of 2026, followed by planning for Phase 3 trials. The company's strategy includes advancing its pipeline through development to regulatory approval, with a near-term focus on the Phase 2 LOTUS trial in HS and preparing to initiate pivotal trials. It also seeks to acquire or in-license rights to and/or develop targeted, complementary preclinical and clinical stage compounds for immune-mediated inflammatory diseases. Additionally, the company may opportunistically out-license rights to compounds, indications, or geographies. Abdabibart (AVTX-009) is a high affinity, highly potent humanized IgG4 monoclonal antibody designed to specifically inhibit IL-1β and block downstream inflammatory pathways. IL-1β is a pro-inflammatory cytokine central to many human diseases, activating immune cells that produce other pro-inflammatory cytokines like IL-6, TNF-α, and IL-17. Dysregulated IL-1β signaling drives inflammation and contributes to autoimmune disorders, and IL-1β inhibition has shown effectiveness in various immune-mediated inflammatory diseases.

Avalo Therapeutics, Inc. (NASDAQ:AVTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for AVTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for AVTX spans 10-Q, 8-K, 424B5, DEF 14A.

Recent high-impact activity:

  • Q3 Loss Narrower Than Expected as Avalo Beats Consensus by $8M
  • Avalo Q3 Loss Narrows to $18.9M; $462.8M Cash Funds Operations Into 2029, But Goodwill Impairment Risk Flagged
  • Avalo Posts Wider Q2 Loss, Positive Phase 2 Data, and Cash Runway Through 2029
  • Avalo Posts $36.4M Q2 Loss, Cash at $472M; Phase 3 for Abdakibart in HS Set for H1 2027
  • Avalo Therapeutics Appoints Biotech Veteran Ron Philip to Board of Directors

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$59K
Net Income
-$78.26M
Diluted EPS
-$5.84
Op. Cash Flow
-$51.46M
Operating Income
-$72.92M
Cash & Equivalents
$15.86M
Debt / Equity
0.00×
Net Margin
-1326.42×
Shares Outstanding
18.51M sh
Source: 10-K · filed 2026-03-23 · accession 0001534120-26-000011

Short Interest & Short Volume

2.09 days to cover

FINRA reported short interest of 8,910,655 shares in AVTX as of the October 30, 2026 settlement, a 25.5% decrease from the prior period — about 2.1 days to cover at its recent average daily volume. On November 20, 2026, 36.6% of AVTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)8,910,655 shares as of October 30, 2026
Change vs prior period▼ 25.5%
Days to cover2.09 at avg daily volume of 4,261,998
Daily short volume (FINRA facilities)36.6% of 315,663 shares on November 20, 2026
5-day average short volume37.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for AVTX, detected from its recent SEC filings · based on capital-structure filings through 2026-11-05.

1 recent capital raise2 shelf registrations

New $200M ATM With Jefferies · Jefferies Takes Up to 3.0%

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$6.76
52-week range · as of 2026-11-05 $6.53 – $24.27
Market cap
$390.88M
Volume
1.2M (0.4× avg)
3-mo avg 2.7M
Live data · 2026-11-21 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AVTX - Latest Insights

AVTX
Nov 05, 2026, 7:58 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $6.91
Real-time Price: $6.76 info
Change: -$0.150 (-2%) info
Market Cap: $390.884M info
AVTX
Nov 05, 2026, 7:04 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.13
Real-time Price: $6.76 info
Change: -$0.370 (-5%) info
Market Cap: $390.884M info
AVTX
Aug 06, 2026, 7:03 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.69
Real-time Price: $6.76 info
Change: -$11.93 (-64%) info
Market Cap: $390.884M info
AVTX
Aug 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.69
Real-time Price: $6.76 info
Change: -$11.93 (-64%) info
Market Cap: $390.884M info
AVTX
Jun 23, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.04
Real-time Price: $6.76 info
Change: -$8.28 (-55%) info
Market Cap: $390.884M info
AVTX
Jun 16, 2026, 7:18 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.80
Real-time Price: $6.76 info
Change: -$8.04 (-54%) info
Market Cap: $390.884M info
AVTX
Jun 16, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.80
Real-time Price: $6.76 info
Change: -$8.04 (-54%) info
Market Cap: $390.884M info
AVTX
Jun 12, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.72
Real-time Price: $6.76 info
Change: -$7.96 (-54%) info
Market Cap: $390.884M info
AVTX
May 13, 2026, 7:02 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $20.46
Real-time Price: $6.76 info
Change: -$13.70 (-67%) info
Market Cap: $390.884M info
AVTX
May 13, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.46
Real-time Price: $6.76 info
Change: -$13.70 (-67%) info
Market Cap: $390.884M info
AVTX
May 07, 2026, 6:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $21.61
Real-time Price: $6.76 info
Change: -$14.85 (-69%) info
Market Cap: $390.884M info
AVTX
May 06, 2026, 7:38 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $22.00
Real-time Price: $6.76 info
Change: -$15.24 (-69%) info
Market Cap: $390.884M info
AVTX
May 06, 2026, 7:36 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $22.00
Real-time Price: $6.76 info
Change: -$15.24 (-69%) info
Market Cap: $390.884M info
AVTX
May 05, 2026, 11:35 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $24.15
Real-time Price: $6.76 info
Change: -$17.39 (-72%) info
Market Cap: $390.884M info
AVTX
May 05, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $16.40
Real-time Price: $6.76 info
Change: -$9.64 (-59%) info
Market Cap: $390.884M info
AVTX
May 05, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $22.99
Real-time Price: $6.76 info
Change: -$16.23 (-71%) info
Market Cap: $390.884M info
AVTX
Apr 28, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.42
Real-time Price: $6.76 info
Change: -$7.66 (-53%) info
Market Cap: $390.884M info
AVTX
Apr 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.42
Real-time Price: $6.76 info
Change: -$7.66 (-53%) info
Market Cap: $390.884M info
AVTX
Apr 23, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.71
Real-time Price: $6.76 info
Change: -$7.95 (-54%) info
Market Cap: $390.884M info
AVTX
Apr 10, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $13.50
Real-time Price: $6.76 info
Change: -$6.74 (-50%) info
Market Cap: $390.884M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets